BLI Banque de Luxembourg Investments Invests $12.46 Million in Becton, Dickinson and Company (NYSE:BDX)

BLI Banque de Luxembourg Investments bought a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 55,000 shares of the medical instruments supplier's stock, valued at approximately $12,459,000.

A number of other large investors have also bought and sold shares of BDX. Brighton Jones LLC increased its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares in the last quarter. E. Ohman J or Asset Management AB increased its position in Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock valued at $39,951,000 after acquiring an additional 20,859 shares in the last quarter. Busey Bank raised its stake in shares of Becton, Dickinson and Company by 3.8% in the fourth quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier's stock worth $15,031,000 after acquiring an additional 2,399 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of Becton, Dickinson and Company by 31.0% during the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier's stock worth $647,082,000 after purchasing an additional 673,568 shares in the last quarter. Finally, ORG Partners LLC grew its stake in shares of Becton, Dickinson and Company by 689.4% during the fourth quarter. ORG Partners LLC now owns 3,205 shares of the medical instruments supplier's stock valued at $727,000 after purchasing an additional 2,799 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $168.61 on Friday. Becton, Dickinson and Company has a 1-year low of $166.11 and a 1-year high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The firm has a market cap of $48.41 billion, a PE ratio of 28.01, a P/E/G ratio of 1.63 and a beta of 0.35. The business's 50-day moving average price is $214.76 and its two-hundred day moving average price is $225.60.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Becton, Dickinson and Company's quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.17 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a stock buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 69.10%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the firm's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the transaction, the executive vice president now directly owns 4,887 shares of the company's stock, valued at $964,107.36. This trade represents a 8.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard Byrd sold 1,940 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total transaction of $436,325.40. Following the sale, the executive vice president now directly owns 7,411 shares of the company's stock, valued at approximately $1,666,808.01. This trade represents a 20.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,578 shares of company stock worth $795,986 over the last ninety days. Insiders own 0.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on BDX shares. Raymond James cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Friday. Stifel Nicolaus lowered their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday. Bank of America lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a report on Thursday. Finally, Piper Sandler downgraded Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their price target for the company from $260.00 to $185.00 in a research note on Friday. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $235.88.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.